Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of dopamine receptor 1 antagonist in preparing drugs for treatment of ketamine-induced schizoid symptoms in mice

A technology for schizophrenia and dopamine is applied in the field of dopamine receptor 1 antagonists, the preparation of drugs for treating schizophrenia induced by ketamine in mice, which can solve the problem of unknown etiology of schizophrenia, and no dopamine receptor 1 antagonist has been found yet. , the lack of biological detection indicators and other problems

Inactive Publication Date: 2020-02-25
中国医科大学
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The etiology of schizophrenia is unknown, and there are few studies on its pathogenesis at present. The clinical diagnosis mainly depends on the judgment of positive symptoms and negative symptoms, and there is a lack of objective biological detection indicators. Its treatment has always been a difficult problem in the medical field. So far, no dopamine receptor 1 antagonist has been found as a target for treating or alleviating the onset of schizophrenia. Therefore, the development of a drug for the treatment of ketamine-induced schizophrenia in mice is a new topic to be solved urgently.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dopamine receptor 1 antagonist in preparing drugs for treatment of ketamine-induced schizoid symptoms in mice
  • Application of dopamine receptor 1 antagonist in preparing drugs for treatment of ketamine-induced schizoid symptoms in mice
  • Application of dopamine receptor 1 antagonist in preparing drugs for treatment of ketamine-induced schizoid symptoms in mice

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0031] 1. Animal preparation and drug injection.

[0032] C57BL / 6 mice, male, 8 weeks old, SPF grade, raised in 12 / 12 circadian rhythm, room temperature 20-22°C, adequate diet and food laboratory. Several mice were randomly divided into two groups: normal saline treatment group (NC, negative control) and high-dose ketamine treatment group (HK, high ketamine). The drug treatment of two groups of mice was carried out by intraperitoneal injection, the administration time was 17:00-18:00, and the injection volume of each mouse was 100ul / 10g. Both the normal saline group and the high-dose ketamine group were administered for seven consecutive days. Finally, the final concentration of ketamine in mice was 100 mg / kg.

[0033] After seven days of high-dose ketamine treatment, the mice were intraperitoneally injected with DRD1 receptor antagonist SCH23390 at a final concentration of 5 mg / kg for seven days.

[0034] 2. Behavioral testing.

[0035] 2.1 Open field experiment.

[0036...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biomedicine and particularly relates to a novel pharmaceutical use of a dopamine receptor 1 antagonist, and to a novel use of the dopamine receptor 1 antagonist in preparing drugs for the treatment of ketamine-induced schizoid symptoms in mice. The dopamine receptor 1 antagonist is selected from SCH23390 having a molecular formula of C17H18ClNO.HCl,and is one or only one effective ingredient to the drugs. A drug for the treatment of ketamine-induced schizoid symptoms in mice comprises the dopamine receptor 1 antagonist having the effective amount (5 mg / kg). The dopamine receptor 1 antagonist is used as one means to treat ketamine-induced schizoid behaviors of mice, and scientific basis is provided for the research and development of a methodto effectively relieve schizoid symptoms in mice.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a new medicinal use of a dopamine receptor 1 antagonist, in particular to a new use of a dopamine receptor 1 antagonist in preparing a medicine for treating schizophrenia in mice induced by ketamine. Background technique [0002] Schizophrenia is the most serious, the most harmful, and the highest disability rate among mental diseases. Its clinical manifestations include thinking disorders (loose thinking, lack of thinking, delusions, etc.), hallucinations, affective disorders (apathy, emotional perversion), behavioral disorders (social withdrawal, strange behavior, nervous excitement, etc.) and loss of learning and working memory. . With the deterioration of social environment and the increase of life pressure, the incidence of schizophrenia is increasing year by year. [0003] Modern medicine believes that schizophrenia is a collection of symptoms and signs of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/55A61P25/18
CPCA61K31/55A61K45/00A61P25/18
Inventor 姚军王保捷吴雪刘永萍曾阔李晓瑾邢佳鑫宣金锋夏皙
Owner 中国医科大学
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products